Anmol Baranwal

17PUBLICATIONS
52CO-AUTHORS
Transplantation immunologyHaematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Medical virology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|May 05, 2026
Single dose antithymocyte globulin effectively reduces GVHD and improves survival in patient undergoing myeloablative matched sibling alloHCT.

|Sep 04, 2025
Risk of Relapse Post Reduced Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With High-Risk Myeloid Neoplasms Based on GvHD Prophylaxis: PTCy Vs. TAC/MTX.

Khalil Hassan, Anmol Baranwal, Al Rabee Kassis

|Jul 29, 2025
Outcomes of Post-Transplant Rh-GCSF and Decitabine Maintenance Therapy in Patients With High-Risk Myeloid Neoplasm.

Mathias Palmer, Anmol Baranwal, Rami Basmaci

|May 07, 2025
Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort.

Mithun Vinod Shah, Kevin Hung, Anmol Baranwal

|Apr 05, 2025
Outcomes of attenuated dose fludarabine and melphalan based conditioning regimen in patients undergoing allogeneic stem cell transplant: a propensity score-matched analysis.

Anmol Baranwal, Rabee Kassis, Khalil Hassan

|Mar 14, 2025
Factors associated with survival after allogeneic transplantation for myeloid neoplasms harboring TP53 mutations.

Anmol Baranwal, Kimberly J Langer, Vedavyas Gannamani

Pageof 3

Frequent Collaborators

15 joint publications

Mithun Vinod Shah

8 joint publications

Mark R Litzow

7 joint publications

Mrinal M Patnaik

7 joint publications

William J Hogan